Pyxis Oncology (NASDAQ:PYXS) Given “Buy” Rating at HC Wainwright

Pyxis Oncology (NASDAQ:PYXS)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $5.00 price target on the stock, down from their prior price target of $7.00. HC Wainwright’s target price would suggest a potential upside of 221.54% from the company’s current price.

A number of other equities research analysts have also recently issued reports on PYXS. William Blair cut shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. Stephens assumed coverage on Pyxis Oncology in a report on Friday, November 8th. They set an “overweight” rating and a $13.00 price objective for the company. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $8.00 target price (down previously from $10.00) on shares of Pyxis Oncology in a research note on Friday. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.43.

Pyxis Oncology Price Performance

PYXS stock traded up $0.02 during mid-day trading on Friday, reaching $1.56. The company had a trading volume of 282,837 shares, compared to its average volume of 789,306. The company has a market capitalization of $92.47 million, a price-to-earnings ratio of -1.51 and a beta of 1.00. Pyxis Oncology has a 52 week low of $1.49 and a 52 week high of $6.85. The stock has a 50 day simple moving average of $2.96 and a two-hundred day simple moving average of $3.31.

Insider Buying and Selling at Pyxis Oncology

In other news, CFO Pamela Ann Connealy bought 88,850 shares of the firm’s stock in a transaction on Tuesday, November 26th. The shares were purchased at an average cost of $1.96 per share, with a total value of $174,146.00. Following the acquisition, the chief financial officer now directly owns 1,199,143 shares in the company, valued at $2,350,320.28. This represents a 8.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 9.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in PYXS. Blue Owl Capital Holdings LP bought a new stake in Pyxis Oncology during the second quarter worth $3,462,000. Millennium Management LLC lifted its position in shares of Pyxis Oncology by 125.3% during the 2nd quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock worth $4,425,000 after buying an additional 743,499 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Pyxis Oncology in the third quarter valued at about $1,405,000. State Street Corp grew its position in Pyxis Oncology by 28.0% in the third quarter. State Street Corp now owns 951,251 shares of the company’s stock valued at $3,491,000 after acquiring an additional 208,344 shares during the last quarter. Finally, abrdn plc grew its position in Pyxis Oncology by 28.9% in the third quarter. abrdn plc now owns 913,045 shares of the company’s stock valued at $3,351,000 after acquiring an additional 204,742 shares during the last quarter. 39.09% of the stock is owned by institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.